Loading...
XKRX
140410
Market cap1.01bUSD
Jul 10, Last price  
56,600.00KRW
1D
3.47%
1Q
-35.02%
Jan 2017
146.09%
IPO
202.67%
Name

Mezzion Pharma Co Ltd

Chart & Performance

D1W1MN
XKRX:140410 chart
P/E
—
P/S
191.36
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.14%
Rev. gr., 5y
-22.69%
Revenues
7.91b
-8.15%
17,920,424,00028,634,181,00026,653,873,00030,726,176,00031,720,932,0008,611,621,0007,909,500,000
Net income
-34.93b
L+79.34%
-23,301,227,000-13,829,312,000-13,602,674,000-36,297,830,000-12,728,376,000-19,476,775,000-34,928,862,000
CFO
-16.59b
L-10.28%
-20,880,005,000-7,376,696,000-15,071,356,690-12,074,641,580-11,023,300,730-18,489,352,000-16,588,063,311
Dividend
Dec 27, 201275 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mezzion Pharma Co., Ltd. operates as a pharmaceutical enterprise focused on the discovery, production, and licensing of various medical treatments. The company's therapeutic offerings target conditions such as erectile dysfunction, benign prostatic hyperplasia, and Fontan disease. Established by Park, Dong-Hyun on September 25, 2002, its corporate base is located in Seoul, South Korea.
URL
https://www.mezzion.co.kr/
IPO date
Jan 20, 2012
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT